USGet the app
Business

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?

Fool·
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie and Eli Lilly offer investors contrasting prospects as pharmaceutical companies adapt to patent expirations and rising demand for metabolic-health treatments. Lilly’s revenue is growing rapidly on the strength of its weight-loss and diabetes medicines, while AbbVie is relying on newer immunology drugs Skyrizi and Rinvoq to replace older revenue. AbbVie trades at a lower valuation, while Lilly’s growth and market position come with a higher price for investors.

Read more at fool.com
Ad
0Like0Dislike0Comments0Shares

Comments 0

No comments yet. Be the first to share your view in the app.

Join the discussion: comments and votes are in the free Beloud app.